Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this protocol is to study the effect of the standard of care in
hepatitis C (pegylated interferon and ribavirin) associated with therapeutic vaccine TG4040
on the viral load of treatment-naïve patients with chronic genotype 1 hepatitis C infection.